| With FDA OK, Amgen’s Heart Drug Faces Rival (And Health Budgets) | Alex Lash | 08/27/15 | National |
| FDA OKs Cholesterol Fighter Praluent For More Patients Than Expected | Alex Lash | 07/24/15 | New York |
| With PCSK9’s Origins In Mind, Sanofi Has UT Join Funding Program | David Holley | 07/09/15 | Texas |
| FDA Cuts Limit on Esperion Cholesterol Drug, Considers Competitors | David Holley | 07/07/15 | Detroit Ann Arbor |
| Retooled Catabasis Cuts Price, Upsizes to Grab $60M in IPO | Ben Fidler | 06/25/15 | Boston |
| Advisors to FDA: Approve New Cholesterol Drug, But With Caveats | Alex Lash | 06/10/15 | National |
| Take a Grain of Salt (Or Two) With New Cholesterol Drug Predictions | Alex Lash | 06/09/15 | National |
| West Coast Biotech Roundup: Mapp Bio, Calico, Alder, VentiRx & More | Alex Lash | 09/04/14 | San Diego |
| Regeneron, Sanofi Pass First Key Test With Cholesterol-Lowering Drug | Ben Fidler | 10/16/13 | New York |
| FDA Staff Issues Positive Report for Aegerion’s Lomatapide | Catherine Arnst | 10/15/12 | Boston |
| Alnylam Gets First Hint of Effectiveness for RNAi Cholesterol-Lowering Drug | Luke Timmerman | 01/04/12 | Boston |
| Alder Steers Next Antibodies To Unusual Places: Treating Migraines and High Cholesterol | Luke Timmerman | 03/02/11 | Seattle |
| How Lilly Let Telaprevir Go to Vertex, SV Focusing on Health IT With Latest Fund, Genzyme Isis Cholesterol Drug Shows Strong in Clinical Trial, & More Boston-Area Life Sciences News | Erin Kutz | 08/06/10 | Boston |
| Genzyme, Isis Cholesterol Drug Passes Pair of Clinical Trials; Shares Fall Anyway | Luke Timmerman | 08/04/10 | Boston |
| SonoSite’s New Push: Ultrasound for an Up-Close Look at Heart Attack Risk | Luke Timmerman | 07/26/10 | Seattle |
| Lessons Learned About the Outlook for New Obesity Drug Approval | Tom Hughes | 07/16/10 | National |
| West Wireless Names CEO, Amylin Pharmaceuticals Awaits FDA Deadline, Life Technologies In Cancer Research Partnership, & More San Diego Life Sciences News | Denise Gellene | 03/11/10 | San Diego |
| Isis Nabs $6M Bristol Payment | Luke Timmerman | 03/08/10 | San Diego |
| Isis, Genzyme Cholesterol Drug Passes Test, But Investors Get Nervous About Liver Safety | Luke Timmerman | 11/17/09 | San Diego |
| Isis CEO Vows that Cholesterol Drug, Partnered With Genzyme, Will be “Remarkable” Advance | Luke Timmerman | 10/21/09 | San Diego |
| Oscient Pharma Seeks Bankruptcy, Finds Buyer for No. 2 Product | Ryan McBride | 07/14/09 | Boston |
| Genzyme, Isis Cholesterol Drug Reaches Goal in Pivotal Study, Paving the Way to FDA | Luke Timmerman | 05/20/09 | Boston |
| Genzyme, Isis Begin New Drug Trials | Ryan McBride | 01/12/09 | Boston |
| Genzyme Thinks Small, and Big, With Cholesterol-Lowering Drug Mipomersen | Luke Timmerman | 09/29/08 | Boston |
| Genzyme, Isis Start Pivotal Trial for High Cholesterol | Luke Timmerman | 08/06/08 | Boston |
| MediQuest Therapeutics Persuades FDA to Do 6-Month Review of Lead Product | Luke Timmerman | 06/25/08 | Seattle |
| Genzyme, Isis Finalize Partnership For Cholesterol-Lowering Drug | Luke Timmerman | 06/24/08 | Boston |
